ArticleCureus2025
Tacrolimus-Associated Hyperpigmentation: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topical tacrolimus is an immunomodulator commonly used in the management of vitiligo. We report a case of tacrolimus-associated hyperpigmentation in a nine-year-old girl with non-segmental vitiligo, who presented with depigmented patches on the eyelid and trunk. The depigmented eyelid patch improved with topical tacrolimus but developed localized, paradoxical hyperpigmentation at the treated site. She was managed with alternating topical corticosteroids and tacrolimus alongside photoprotection; after six weeks, the trunk demonstrated full repigmentation, but the eyelid lesion developed marked hyperpigmentation temporally associated with tacrolimus use. Other causes of pigmentation were excluded, and the discoloration resolved completely within six weeks of discontinuing treatment. To further examine this presentation, we reviewed the literature for reports of similar pigmentary changes associated with tacrolimus. This review encompassed both oral and topical use in patients with and without vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.